{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:37:00Z","timestamp":1783769820717,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009330","name":"Medical Science and Technology Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Non-chemotherapy drug-induced agranulocytosis (NCDIA) is a serious adverse reaction that significantly increases the risk of life-threatening infections. Although the association between certain non-chemotherapy drugs and agranulocytosis has been documented, a comprehensive analysis using a large-scale pharmacovigilance database is lacking. This study aimed to systematically identify and characterize NCDIA by analyzing adverse event reports from the FAERS database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis of NCDIA reports from the FAERS database spanning from 2004 to 2024 Q1. Drugs were classified using the Anatomical Therapeutic Chemical (ATC) classification system, with chemotherapy agents (ATC code L01) excluded. The Reporting Odds Ratio (ROR) method was employed to detect potential adverse event signals. Positive signals were defined as cases with at least three reports and a lower 95% confidence interval (CI) of ROR greater than one. Time-to-event analysis was also performed to examine onset patterns across different demographic groups and drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 10,913 NCDIA reports were identified from the FAERS database. Disproportionality analysis revealed significant signals for 166 non-chemotherapy drugs related to agranulocytosis, which were systematically classified into three risk categories: known (n = 111), possible (n = 25), and new potential risks (n = 30). This classification system enables us to identify drugs with known risks, those that might pose a risk, and new risks warranting further investigation. Demographic analysis revealed that females, children (&amp;lt;18\u00a0years), and the elderly (\u226565\u00a0years) experienced earlier onset of agranulocytosis. Drug-specific onset timing analysis provided evidence for optimizing monitoring protocols. Notably, NCDIA-associated mortality rates showed a significant decrease from 11.91% (2004\u20132010) to 7.28% (2021\u20132024) (<jats:italic>P<\/jats:italic> &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This comprehensive pharmacovigilance study not only confirmed previously known NCDIA associations but also identified new potential risk drugs. The novel risk classification system and detailed onset timing analysis provide valuable insights for clinical monitoring. The findings of earlier onset in specific populations and declining mortality trends have important implications for developing targeted surveillance strategies and improving patient safety management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1525307","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:11:53Z","timestamp":1741158713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Shanshan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaokai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (Review article)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/ajh.25483","article-title":"Immune neutropenia mediated by micafungin","volume":"94","author":"Ameri","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andr\u00e8S","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14740338.2017.1376645","article-title":"Non-chemotherapy drug-induced neutropenia - an update","volume":"16","author":"Andres","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/qjmed\/hcw220","article-title":"Idiosyncratic drug-induced neutropenia and agranulocytosis","volume":"110","author":"Andres","year":"2017","journal-title":"QJM"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/jcm8091351","article-title":"State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies","volume":"8","author":"Andres","year":"2019","journal-title":"J. Clin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/ehm.11.12","article-title":"Clinical presentation and management of drug-induced agranulocytosis","volume":"4","author":"Andres","year":"2011","journal-title":"Expert Rev. Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"102155","DOI":"10.1016\/j.msard.2020.102155","article-title":"Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab","volume":"43","author":"Auer","year":"2020","journal-title":"Multiple Scler. Relat. Disord."},{"key":"B10","volume-title":"Drug-induced neutropenia and agranulocytosis","author":"Coates","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/092986710790416326","article-title":"Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions","volume":"17","author":"Corsonello","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/asheducation-2017.1.187","article-title":"Non-chemotherapy drug-induced neutropenia: key points to manage the challenges","volume":"2017","author":"Curtis","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"44","author":"Gandhi","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1517\/14740338.6.3.323","article-title":"Non-chemotherapy drug-induced agranulocytosis","volume":"6","author":"Garbe","year":"2007","journal-title":"Expert Opin. drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1176\/ps.47.1.52","article-title":"Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis","volume":"47","author":"Honigfeld","year":"1996","journal-title":"Psychiatr. Serv. Wash. DC"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1431941","DOI":"10.3389\/fphar.2024.1431941","article-title":"Predicting non-chemotherapy drug-induced agranulocytosis toxicity through ensemble machine learning approaches","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B17","first-page":"15","article-title":"FDA adverse event reporting system (FAERS) database: a comprehensive analysis of its structure, functionality, and limitations","volume":"5","author":"Ismail","year":"2022","journal-title":"Sage Sci. Rev. Appl. Mach. Learn."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2169\/internalmedicine.48.2093","article-title":"Azithromycin-related agranulocytosis in an elderly man with acute otitis media","volume":"48","author":"Kajiguchi","year":"2009","journal-title":"Intern. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2169\/internalmedicine.53.2085","article-title":"Clostridium difficile infection induced by pregabalin-associated agranulocytosis","volume":"53","author":"Kino","year":"2014","journal-title":"Intern. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","article-title":"Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data","volume":"120","author":"Lalami","year":"2017","journal-title":"Crit. Rev. oncology\/hematology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11096-008-9218-3","article-title":"Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma","volume":"30","author":"Laporte","year":"2008","journal-title":"Pharm. World and Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1179\/1973947815Y.0000000032","article-title":"Thrombocytopaenia and neutropaenia associated with daptomycin USE","volume":"28","author":"Leyra","year":"2016","journal-title":"J. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3390\/jcm9061808","article-title":"Idiosyncratic drug-induced neutropenia and agranulocytosis in elderly patients","volume":"9","author":"Lorenzo-Villalba","year":"2020","journal-title":"J. Clin. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit. Rev. oncology\/hematology"},{"key":"B26","first-page":"470","article-title":"Prognostic factors of hematologic recovery in nonchemotherapy drug-induced agranulocytosis","volume":"88","author":"Maloisel","year":"2003","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1186\/s12879-023-08652-8","article-title":"Fosfomycin-induced agranulocytosis: a case report and review of the literature","volume":"23","author":"Matusik","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/08880018.2016.1234523","article-title":"Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program","volume":"33","author":"Medrano-Casique","year":"2016","journal-title":"Pediatr. Hematol. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann. Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1210\/jc.2013-2569","article-title":"Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan","volume":"98","author":"Nakamura","year":"2013","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2165\/00002018-199309060-00009","article-title":"Relevance of in vitro studies of drug-induced agranulocytosis: report of 14 cases","volume":"9","author":"Parent-Massin","year":"1993","journal-title":"Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"727717","DOI":"10.3389\/fphar.2021.727717","article-title":"Drug-induced idiosyncratic agranulocytosis - infrequent but dangerous","volume":"12","author":"Rattay","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"20143085","DOI":"10.1098\/rspb.2014.3085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc. R. Soc. B Biol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1525307\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:11:57Z","timestamp":1741158717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1525307\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":35,"alternative-id":["10.3389\/fphar.2025.1525307"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1525307","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"article-number":"1525307"}}